Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system

Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system

AimThe aim of this study was to identify potential safety concerns associated with Sacituzumab Govitecan (SG), an antibody-drug conjugate targeting trophoblastic cell-surface antigen-2, by analyzing real-world safety data from the largest publicly available worldwide pharmacovigilance database.Metho...

Full description

Bibliographic Details
Main Authors: Xiujuan Gui, Jianli Zhao, Linxiaoxiao Ding, Jie Chai, Hongna Lai, Yangyang Cai, Simin Luo, Yinduo Zeng, Wenjing Wu, Haizhu Chen, Herui Yao, Ying Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
Sacituzumab govitecan
FAERS
safety
pharmacovigilance
pneumonitis
sepsis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1276976/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1276976/full

Similar Items